Evofem Biosciences (EVFM) Misses Q3 EPS by 34c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. CRWD
2. REGN
3. LITE
4. ABBV
5. CL
6. MRVL
7. LYB
8. TFII
9. NVT
10. SPY

Go back to Evofem Biosciences (EVFM) Misses Q3 EPS by 34c

Evofem Biosciences Reports Third Quarter 2018 Financial Results and Provides Corporate Update

November 7, 2018 6:51 AM EST

SAN DIEGO, Nov. 7, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), today reported financial results for the three- and nine- month periods ended September 30, 2018. Recent highlights include:

Last patient visit is imminent in AMPOWER, the second Phase 3 trial of Amphora, its lead Multipurpose Vaginal pH Regulator (MVP-R) product candidate, for non-hormonal birth control; anticipating top-line results by year-end 2018; Completed 'User Experience Satisfaction Survey' among women who completed AMPOWER along with their male partners; and, Advanced patient enrollment in Phase 2b clinical trial... More